• An Open Letter to the Chronically Ill Professional
  • Northern Ireland Reaches Deal With Vertex for Access to Kaftrio
  • Real-world Impact of Trikafta Will Be Evaluated in RECOVER Study
  • Thread-based Wearable Device May Help Diagnose, Monitor CF and Other Conditions
  • CFF Impact Grants Go to 4 Online Programs Engaging Patients, Community
  • Diagnosis Privilege Can Be a Form of Discrimination
  • CF Canada Honors thyssenkrupp Elevator Canada with National Champion Award
  • AzurRx Begins Phase 2b Trial Testing MS1819 for Pancreatic Insufficiency in CF Patients
  • Plan A Didn’t Work — Now What?
  • CF Patients in Wales Will Have Access to Kaftrio Under New Deal
  • ContraFect Given Up to $18.9M to Advance CF-370 for P. aeruginosa Infections
  • Inflammatory Markers May Help Predict Exacerbations in Children with CF